With the cell and gene therapy field maturing rapidly, the question on everyone’s mind heading into 2025 is no longer what can be done, but how it should be done – and for whom. The scientific breakthroughs are undeniable, but the real challenge now lies in converting potential into scalable, sustainable, and accessible treatments.
Working with IB Communications as roving reporters, we asked industry leaders: What should be the top priorities for the cell and gene sector in 2025?
From embedding scalability into early development, to improving patient access, reducing manufacturing costs, harmonizing regulations, and rethinking how academia and industry collaborate, there’s a clear call for the sector to evolve strategically.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
